Windlas Biotech Limited (WINDLAS.BO)
Windlas Biotech Limited operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Dehradun, IN. The stock last traded at $949.45, up 0.17% on the session, giving a market capitalisation of $20.08B. Its beta of 0.27 implies it has historically moved less than the broad market.
Operating as a Contract Development and Manufacturing Organization (CDMO), Windlas Biotech Limited is engaged in the manufacturing and global trade of pharmaceutical products, serving markets across India and internationally. Its comprehensive CDMO offerings span the full spectrum from product discovery and development to licensing and the large-scale commercial production of generic pharmaceuticals. The company also extends its expertise to the creation of nutraceutical supplements. Windlas Biotech's manufacturing capabilities encompass diverse dosage forms such as tablets, capsules, pouches, sachets, and liquid bottles. Its generic product lineup features a broad array of solutions, including standard fixed-dose combinations, advanced fixed-dose plus modified-release combinations, bespoke customized generics, and convenient chewable or dispersible options. Established in 2001, Windlas Biotech Limited is based in Gurugram, India.
Windlas Biotech Limited is most often compared with the following Healthcare names: